Zobrazeno 1 - 10
of 116
pro vyhledávání: '"Hiroyuki, Yasojima"'
Autor:
Emi Noguchi, Takashi Yamanaka, Hirofumi Mukai, Naohito Yamamoto, Chi-Feng Chung, Yen-Shen Lu, Dwan-Ying Chang, Joohyuk Sohn, Gun Min Kim, Kyung-Hun Lee, Soo-Chin Lee, Tsutomu Iwasa, Hiroji Iwata, Kenichi Watanabe, Kyung Hae Jung, Yuko Tanabe, Seok Yun Kang, Hiroyuki Yasojima, Kenjiro Aogi, Eriko Tokunaga, Sung Hoon Sim, Yoon Sim Yap, Koji Matsumoto, Ling-Ming Tseng, Yoshiko Umeyama, Kazuki Sudo, Yuki Kojima, Tomomi Hata, Aya Kuchiba, Taro Shibata, Kenichi Nakamura, Yasuhiro Fujiwara, Kenji Tamura, Kan Yonemori
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-10 (2024)
Abstract Palbociclib combined with endocrine therapy is approved for treating patients with hormone-receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer; however, data on palbociclib combined with t
Externí odkaz:
https://doaj.org/article/3cba658e7441401e9b9e50ad16a29171
Autor:
Masaya Hattori, Norikazu Masuda, Toshimi Takano, Koichiro Tsugawa, Kenichi Inoue, Koji Matsumoto, Takashi Ishikawa, Mitsuya Itoh, Hiroyuki Yasojima, Yuko Tanabe, Keiko Yamamoto, Masato Suzuki, Wilbur Pan, Javier Cortes, Hiroji Iwata
Publikováno v:
Cancer Medicine, Vol 12, Iss 9, Pp 10280-10293 (2023)
Abstract Pembrolizumab plus chemotherapy improved progression‐free survival (PFS) and overall survival (OS) compared with placebo plus chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic triple‐negative b
Externí odkaz:
https://doaj.org/article/d6b16a26e787415ab7f68851b17b9f97
Autor:
Ken Yoshida, Tadayuki Kotsuma, Yuji Takaoka, Setsuo Tamenaga, Hideya Yamazaki, Takayuki Nose, Naoya Murakami, Koji Inaba, Hironori Akiyama, Koji Masui, Tadashi Takenaka, Hikaru Kubota, Nikolaos Tselis, Norikazu Masuda, Hiroyuki Yasojima, Masashi Takeda, Masayuki Mano, Satoaki Nakamura, Keita Utsunomiya, Noboru Tanigawa, Eiichi Tanaka
Publikováno v:
Journal of Contemporary Brachytherapy, Vol 15, Iss 1, Pp 1-8 (2023)
Externí odkaz:
https://doaj.org/article/22d6836ad62745acac401bc9c0742214
Autor:
Hiroji Iwata, Kenichi Yoshimura, Norikazu Masuda, Kenjiro Aogi, Yuko Tanabe, Koji Matsumoto, Masato Takahashi, Hitomi Sakai, Junji Tsurutani, Chiyo K Imamura, Tsutomu Iwasa, Toshimi Takano, Kiyoshi Yoshimura, Jun Masuda, Manabu Futamura, Mari Hosonaga, Toru Mukohara, Sakiko Miura, Toshiko Yamochi, Hidetaka Kawabata, Hiroyuki Yasojima, Nobumoto Tomioka
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 9 (2023)
Background Hormone receptor (HR)-positive breast cancer is a disease for which no immune checkpoint inhibitors have shown promise as effective therapies. Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors synergistically increased the effectiveness
Externí odkaz:
https://doaj.org/article/48eaa440eb16414586e7459b2d147b7c
Autor:
Norikazu Masuda, Kenji Tamura, Hiroyuki Yasojima, Akihiko Shimomura, Masataka Sawaki, Min-Jung Lee, Akira Yuno, Jane Trepel, Ryoko Kimura, Yozo Nishimura, Shigehira Saji, Hiroji Iwata
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-12 (2021)
Abstract Background Entinostat is an oral inhibitor of class I histone deacetylases intended for endocrine therapy-resistant patients with hormone receptor-positive (HR+) advanced or metastatic breast cancer (BC). We examined the safety, efficacy, an
Externí odkaz:
https://doaj.org/article/9dfbd51172f74073a43eee623bd9f903
Autor:
Takahiro Nakayama, Tetsuhiro Yoshinami, Hiroyuki Yasojima, Nobuyoshi Kittaka, Masato Takahashi, Shoichiro Ohtani, Seung Jin Kim, Hiroyuki Kurakami, Naoko Yamamoto, Tomomi Yamada, Takehiko Takata, Norikazu Masuda
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-12 (2021)
Abstract Background Trastuzumab emtansine (T-DM1) is a second-line standard therapy for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. Evidence regarding post–T-DM1 treatments is currently lacking.
Externí odkaz:
https://doaj.org/article/8b02d3fbc4a34996b43ef5c3f608feda
Autor:
Akihiko Shimomura, Kan Yonemori, Masayuki Yoshida, Teruhiko Yoshida, Hiroyuki Yasojima, Norikazu Masuda, Kenjiro Aogi, Masato Takahashi, Yoichi Naito, Satoru Shimizu, Rikiya Nakamura, Akinobu Hamada, Hirofumi Michimae, Jun Hashimoto, Harukaze Yamamoto, Asuka Kawachi, Chikako Shimizu, Yasuhiro Fujiwara, Kenji Tamura
Publikováno v:
Translational Oncology, Vol 12, Iss 10, Pp 1386-1394 (2019)
BACKGROUND: We conducted a phase I/II clinical trial to evaluate the efficacy of eribulin and olaparib in a tablet form (EO study) for triple-negative breast cancer (TNBC) patients. We hypothesized that somatic BRCA mutations and homologous recombina
Externí odkaz:
https://doaj.org/article/dcf6a662f48a4a31ae6c491fcbcde18e
Autor:
Nobuaki Sato, Norikazu Masuda, Takashi Morimoto, Takayuki Ueno, Chizuko Kanbayashi, Koji Kaneko, Hiroyuki Yasojima, Shigehira Saji, Hironobu Sasano, Satoshi Morita, Shinji Ohno, Masakazu Toi
Publikováno v:
Cancer Medicine, Vol 8, Iss 12, Pp 5468-5481 (2019)
Abstract Our aim was to investigate the efficacy and safety of initial neoadjuvant endocrine therapy with exemestane alone followed by tailored treatment, either continued exemestane monotherapy or exemestane plus docetaxel–cyclophosphamide (TC) co
Externí odkaz:
https://doaj.org/article/cffc7a974a64474689d80565a6c14440
Autor:
Nobuaki Sato, Norikazu Masuda, Takashi Morimoto, Takayuki Ueno, Chizuko Kanbayashi, Koji Kaneko, Hiroyuki Yasojima, Shigehira Saji, Hironobu Sasano, Satoshi Morita, Shinji Ohno, Masakazu Toi
Publikováno v:
Cancer Medicine, Vol 7, Iss 7, Pp 3044-3056 (2018)
Abstract Patients with estrogen receptor (ER)‐positive breast cancer are less likely to achieve a pathological complete response (pCR) with neoadjuvant chemotherapy. Neoadjuvant endocrine therapy may be more appropriate than neoadjuvant chemotherap
Externí odkaz:
https://doaj.org/article/e8d269bb8bf9467f9dbaad8dbceb0ec4
Autor:
Fumikata Hara, Makiko Ono, Shigehisa Kitano, Shigehira Saji, Akihiko Shimomura, Takashi Yamanaka, Takayuki Kadoya, Mitsuya Ito, Hiroko Bando, Hiroyuki Yasojima, Keita Sasaki, Tomoko Kataoka, Tadahiko Shien, Kan Yonemori, Hiroji Iwata
Publikováno v:
Cancer Research. 82:OT1-18
Background: Hormone receptor (HR)-positive HER2-negative breast cancers have a lower tumor mutation burden than other types of cancer and triple-negative breast cancer, resulting in relatively low immunogenicity. It is also known that estrogen suppre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ea7a91ade06539f1cb1c32d29f3c950
https://doi.org/10.1158/1538-7445.sabcs21-ot1-18-01
https://doi.org/10.1158/1538-7445.sabcs21-ot1-18-01